Assessment of Prescription Opioid Medical Use and Misuse Among Parents and Their Adolescent Offspring in the US.
Assessment of Prescription Opioid Medical Use and Misuse Among Parents and Their Adolescent Offspring in the US.
复制标题
DOI：
10.1001/jamanetworkopen.2020.31073
复制
发表时间：
2021-01-04
影响因子：
13.8
通讯作者：
Kandel DB
中科院分区：
文献类型：
--
作者：
Griesler PC;Hu MC;Wall MM;Kandel DB
在美国，父母和青少年使用和滥用阿片类药物处方之间的关联模式是什么？在这项全国代表性的横断面研究中，对来自全国药物使用和健康调查的15200名父母-青少年进行了研究，控制了其他因素，过去一年内父母的医疗处方阿片类药物使用与青少年的医疗处方阿片类药物使用和滥用有关，而父母的滥用则无关。这些研究结果表明，减少医生的阿片类药物处方并教育家庭了解限制青少年在家中获得处方阿片类药物的药物使用实践可能是减少青少年处方阿片类药物滥用的重要目标。这项横断面研究探讨了在全国药物使用和健康调查中父母和青少年处方阿片类药物使用和滥用之间的关联。在美国，关于父母和青少年医疗处方阿片类药物使用和滥用之间的关联的信息有限。检查父母和青少年处方阿片类药物使用和滥用之间的关联。这项具有全国代表性的横断面研究包括来自2015-2017年度全国药物使用和健康调查的15200对父母-青少年。数据收集时间为2015年1月6日至2017年12月20日，分析时间为2019年10月4日至2020年10月15日。父母过去12个月的阿片类药物使用和任何滥用（即，在没有处方的情况下使用或以任何方式不受医生指导）。青少年过去12个月的医疗处方阿片类药物使用或滥用。多变量回归估计父母和后代的医疗处方阿片类药物使用或滥用之间的关联，控制社会人口和社会心理变量。受访者包括9400母子和5800父子二人在同一个家庭，儿童年龄在12至17岁（52.8%男性，平均[SD]年龄，14.5 [1.7]岁）。控制其他因素，父母处方阿片类药物使用与青少年处方阿片类药物使用（校正比值比[aOR]，1.28; 95%CI，1.06-1.53）和滥用（aOR，1.53; 95%CI，1.07-2.25）相关，而父母滥用则无关。父母处方兴奋剂使用与青少年处方阿片类药物使用相关（aOR，1.40; 95% CI，1.02-1.91）。父母使用大麻（aOR，1.84; 95%CI，1.13-2.99），父母-青少年冲突（aOR，1.26; 95%CI，1.05-1.52）和青少年抑郁症（aOR，1.75; 95%CI，1.26-2.44）与青少年处方阿片类药物滥用相关。青少年犯罪（aOR，1.55; 95%CI，1.38-1.74）和知觉的同学的药物使用（aOR，2.87; 95%CI，1.95-4.23）也与青少年滥用相关，与医疗使用相关性较弱（aOR分别为1.13 [95% CI，1.05-1.22]和1.61 [95% CI，1.32-1.96]）。青年使用处方类阿片在一定程度上是一个结构/环境问题。这项研究的结果表明，父母的医疗处方阿片类药物的使用与后代的处方阿片类药物的使用相关，而父母的滥用则不然。限制医生对父母的阿片类药物处方是一个至关重要的公共卫生目标。此外，还可以教育父母了解他们对后代使用处方阿片类药物的风险以及减轻风险的做法，包括安全的药物储存和处置。父母处方阿片类药物使用的筛查可能是儿科实践的一部分。解决青少年心理健康问题也可以减少青少年处方阿片类药物滥用。
What are the patterns of association between parental and adolescent medical prescription opioid use and misuse in the US? In this nationally representative cross-sectional study of 15 200 parent-adolescent dyads from the National Survey on Drug Use and Health, controlling for other factors, parental medical prescription opioid use within the past year was associated with adolescent medical prescription opioid use and misuse, whereas parental misuse was not. These findings suggest that reducing opioid prescribing by physicians and educating families about medication use practices that restrict the availability of prescription opioids to adolescents in the home could be important targets for reducing adolescent prescription opioid misuse. This cross-sectional study examines the associations between parental and adolescent prescription opioid medical use and misuse among parent and adolescent dyads in the National Survey on Drug Use and Health. Limited information is available regarding the association between parental and adolescent medical prescription opioid use and misuse in the US. To examine the associations between parental and adolescent prescription opioid medical use and misuse. This cross-sectional, nationally representative study included 15 200 parent-adolescent dyads from the annual 2015-2017 National Survey on Drug Use and Health. Data were collected from January 6, 2015, to December 20, 2017, and analyzed from October 4, 2019, to October 15, 2020. Parental past 12-month exclusive medical prescription opioid use and any misuse (ie, using without a prescription or in any way not directed by a physician). Adolescent past 12-month medical prescription opioid use or misuse. Multivariable regressions estimated associations between parental and offspring medical prescription opioid use or misuse, controlling for sociodemographic and psychosocial variables. Respondents included 9400 mother-child and 5800 father-child dyads in the same household; children were aged 12 to 17 years (52.8% male; mean [SD] age, 14.5 [1.7] years). Controlling for other factors, parental medical prescription opioid use was associated with adolescent prescription opioid medical use (adjusted odds ratio [aOR], 1.28; 95% CI, 1.06-1.53) and misuse (aOR, 1.53; 95% CI, 1.07-2.25), whereas parental misuse was not. Parental medical prescription stimulant use was associated with adolescent medical prescription opioid use (aOR, 1.40; 95% CI, 1.02-1.91). Parental marijuana use (aOR, 1.84; 95% CI, 1.13-2.99), parent-adolescent conflict (aOR, 1.26; 95% CI, 1.05-1.52), and adolescent depression (aOR, 1.75; 95% CI, 1.26-2.44) were associated with adolescent prescription opioid misuse. Adolescent delinquency (aOR, 1.55; 95% CI, 1.38-1.74) and perceived schoolmates’ drug use (aOR, 2.87; 95% CI, 1.95-4.23) were also associated with adolescent misuse and more weakly with medical use (aORs, 1.13 [95% CI, 1.05-1.22] and 1.61 [95% CI, 1.32-1.96], respectively). Youth use of prescription opioids is in part a structural/environmental issue. The findings of this study suggest that parental medical prescription opioid use is associated with offspring prescription opioid use, whereas parental misuse is not. Restricting physicians’ opioid prescribing to parents is a crucial public health goal. In addition, parents could be educated on the risks of their prescription opioid use for offspring and on practices to mitigate risk, including safe medication storage and disposal. Screening for parental prescription opioid use could be part of pediatric practice. Addressing adolescent mental health could also reduce adolescent prescription opioid misuse.
登录
查看更多内容
影响因子：
3.5
作者：
Binswanger IA;Glanz JM
通讯作者：
Glanz JM
影响因子：
39.2
作者：
Han, Beth;Compton, Wilson M.;Jones, Christopher M.
通讯作者：
Jones, Christopher M.
CDC规定慢性疼痛的阿片类药物的指南 - 美国，2016年。
DOI：
10.1001/jama.2016.1464
发表时间：
2016-04-19
期刊：
JAMA
影响因子：
--
作者：
Dowell D;Haegerich TM;Chou R
通讯作者：
Chou R
影响因子：
3.5
作者：
Ford, Jason A.;Rigg, Khary K.
通讯作者：
Rigg, Khary K.
影响因子：
4.2
作者：
Boyd, CJ;McCabe, SE;Teter, CJ
通讯作者：
Teter, CJ